UVA Health: Weight-Loss Drug Tirzepatide Reduces Heart Failure Deaths
November 21, 2024
November 21, 2024
CHARLOTTESVILLE, Virginia, Nov. 21 (TNSres) -- University of Virginia Health issued the following news release:
Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA Health reveals.
The drug, from pharmaceutical company Eli Lilly and Co., was tested in the SUMMIT clinical trial at 146 sites in the United States and abroad. A total . . .
Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with heart failure, preserved heart pump function and obesity, new research from UVA Health reveals.
The drug, from pharmaceutical company Eli Lilly and Co., was tested in the SUMMIT clinical trial at 146 sites in the United States and abroad. A total . . .